Natera stock gains 2.75 percent after Japan test approval

Published on 09/24/2026 at 18:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock traded at USD 401.54 on September 24, 2026, 1.71 percent below its 52-week high. Q2 revenue rose 37.7 percent to USD 752.75 million, while 2026 guidance increased.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera stock (ISIN US6323071042) traded at USD 401.54 on Nasdaq on September 24, 2026, up 2.75 percent and 1.71 percent below its 52-week high of USD 408.51. The move followed Japan's approval of Signatera as a companion diagnostic for muscle-invasive bladder cancer on September 22, 2026, as finanzen.at reported.

Japan approval expands Signatera

The authorization covers Signatera's use in treatment decisions for adjuvant atezolizumab in muscle-invasive bladder cancer. Natera plans a commercial launch in Japan in the first half of 2027, giving the oncology test a defined regulatory and commercial timetable.

The approval is Signatera's second PMDA authorization in Japan after a colorectal cancer approval in June 2026. That sequence matters because it moves the product from clinical validation toward a broader country-level commercial rollout.

Revenue growth outpaces valuation

Natera generated USD 752.75 million of revenue in Q2 2026, a 37.7 percent increase from the same quarter a year earlier, according to Yahoo Finance. Oncology test volumes rose 57.2 percent, while total test volume reached approximately 1.04 million in the quarter.

The company still reported a Q2 2026 net loss of USD 66.97 million, or USD 0.47 per diluted share, but the loss narrowed from USD 0.74 per share in Q2 2025. Management also lifted its 2026 revenue forecast by USD 100 million at the midpoint to USD 2.85 billion-2.91 billion.

Stock remains near yearly high

Natera's market capitalization was USD 57.51 billion on September 24, 2026. The stock's 52-week range was USD 157.43 to USD 408.51, placing the intraday price only USD 6.97 below the upper boundary.

The valuation question now sits beside the operating story. Revenue growth, expanding oncology volumes and the Japan launch timetable support the commercial case, while the quarterly loss shows that scaling the testing platform remains costly.

Trading level on September 24

Natera stock was trading at USD 401.54 on Nasdaq on September 24, 2026 at 12:50 p.m. ET, with a daily gain of 2.75 percent. The market is weighing a new international Signatera opportunity against the company's continuing investment and negative quarterly earnings.